Acura Pharmaceuticals Company Profile (NASDAQ:ACUR)

About Acura Pharmaceuticals (NASDAQ:ACUR)

Acura Pharmaceuticals logoAcura Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. The Company has discovered and developed three platform technologies, which can be used to develop multiple products. The Company's Oxaydo Tablets (oxycodone HCl, CII), which utilizes the Aversion Technology, is an approved and immediate-release (IR) oxycodone product in the United States. The Company's Impede technology products include Nexafed and Nexafed Sinus Pressure + Pain. Its third deterrent technology is Limitx, which is designed to retard the release of active drug ingredients when too many tablets are accidently or purposefully ingested. The Company's Aversion and Limitx technologies are intended to address methods associated with opioid and its Impede technology is directed at the extraction and conversion of pseudoephedrine into methamphetamine.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Delivery
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:ACUR
  • CUSIP: 00509L70
  • Web: acurapharm.com
Capitalization:
  • Market Cap: $9.21 million
  • Outstanding Shares: 20,795,000
Average Prices:
  • 50 Day Moving Avg: $0.45
  • 200 Day Moving Avg: $0.51
  • 52 Week Range: $0.40 - $1.87
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 1.20
  • P/E Growth: 0.00000
Sales & Book Value:
  • Annual Revenue: $6.79 million
  • Price / Sales: 1.36
  • Book Value: ($0.03) per share
  • Price / Book: -16.41
Profitability:
  • EBIDTA: ($1,420,000.00)
  • Net Margins: -2,335.87%
  • Return on Equity: -1,237.56%
  • Return on Assets: -114.20%
Debt:
  • Debt-to-Equity Ratio: -7.29%
  • Current Ratio: 1.25%
  • Quick Ratio: 1.15%
Misc:
  • Average Volume: 10,852 shs.
  • Beta: 2.12
  • Short Ratio: 0.73
 

Frequently Asked Questions for Acura Pharmaceuticals (NASDAQ:ACUR)

What is Acura Pharmaceuticals' stock symbol?

Acura Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACUR."

How were Acura Pharmaceuticals' earnings last quarter?

Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) posted its earnings results on Monday, August, 14th. The company reported ($0.18) EPS for the quarter, missing analysts' consensus estimates of ($0.11) by $0.07. The business had revenue of $0.09 million for the quarter. Acura Pharmaceuticals had a negative net margin of 2,335.87% and a negative return on equity of 1,237.56%. View Acura Pharmaceuticals' Earnings History.

Where is Acura Pharmaceuticals' stock going? Where will Acura Pharmaceuticals' stock price be in 2017?

2 brokers have issued 1-year target prices for Acura Pharmaceuticals' shares. Their forecasts range from $6.00 to $10.00. On average, they expect Acura Pharmaceuticals' stock price to reach $8.00 in the next year. View Analyst Ratings for Acura Pharmaceuticals.

Who are some of Acura Pharmaceuticals' key competitors?

Who are Acura Pharmaceuticals' key executives?

Acura Pharmaceuticals' management team includes the folowing people:

  • Robert B. Jones, President, Chief Executive Officer, Director
  • Peter A. Clemens, Chief Financial Officer, Senior Vice President, Secretary
  • Robert A. Seiser CPA, Vice President, Corporate Controller and Treasurer
  • J. Bradley Rivet, Vice President - Marketing
  • Albert W. Brzeczko Ph.D., Vice President -Technical Affairs
  • James F. Emigh, Vice President - Corporate Development
  • George K. Ross, Independent Director
  • William G. Skelly, Independent Director
  • Immanuel Thangaraj, Independent Director
  • Bruce F. Wesson, Independent Director

Who owns Acura Pharmaceuticals stock?

Acura Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include SCHUTTE JOHN (47.50%). View Institutional Ownership Trends for Acura Pharmaceuticals.

How do I buy Acura Pharmaceuticals stock?

Shares of Acura Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Acura Pharmaceuticals' stock price today?

One share of Acura Pharmaceuticals stock can currently be purchased for approximately $0.44.


MarketBeat Community Rating for Acura Pharmaceuticals (NASDAQ ACUR)
Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  87 (Vote Outperform)
Underperform Votes:  69 (Vote Underperform)
Total Votes:  156
MarketBeat's community ratings are surveys of what our community members think about Acura Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Acura Pharmaceuticals (NASDAQ:ACUR) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $8.00 (1,705.50% upside)

Analysts' Ratings History for Acura Pharmaceuticals (NASDAQ:ACUR)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/21/2016FBR & CoReiterated RatingOutperform$10.00N/AView Rating Details
10/18/2016Roth CapitalSet Price TargetBuy$6.00N/AView Rating Details
(Data available from 9/20/2015 forward)

Earnings

Earnings History for Acura Pharmaceuticals (NASDAQ:ACUR)
Earnings by Quarter for Acura Pharmaceuticals (NASDAQ:ACUR)
Earnings History by Quarter for Acura Pharmaceuticals (NASDAQ ACUR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/14/2017Q2 2017($0.11)($0.18)$0.09 millionViewN/AView Earnings Details
5/12/2017Q1 2017($0.11)$0.03$0.34 million$2.72 millionViewN/AView Earnings Details
11/14/2016Q3($0.27)($0.19)$0.23 million$0.22 millionViewN/AView Earnings Details
8/8/2016Q2($0.28)($0.28)$0.19 million$0.26 millionViewN/AView Earnings Details
5/2/2016Q116($0.26)($0.28)$0.15 million$0.22 millionViewN/AView Earnings Details
2/29/2016Q315($0.03)($0.08)$2.70 million$2.68 millionViewListenView Earnings Details
8/3/2015Q215($0.02)($0.05)$2.90 million$0.34 millionViewN/AView Earnings Details
5/4/2015Q115$0.07$0.03$7.60 million$5.40 millionViewN/AView Earnings Details
3/2/2015Q414($0.09)($0.06)$0.05 million$0.53 millionViewN/AView Earnings Details
11/3/2014Q3 2014($0.08)($0.06)$0.05 million$0.15 millionViewN/AView Earnings Details
3/3/2014Q4 13($0.06)($0.29)ViewN/AView Earnings Details
8/1/2013Q2 2013($0.07)ViewN/AView Earnings Details
3/4/2013Q4 2012($0.86)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Acura Pharmaceuticals (NASDAQ:ACUR)
Current Year EPS Consensus Estimate: $-0.46000 EPS
Next Year EPS Consensus Estimate: $0.37000 EPS

Dividends

Dividend History for Acura Pharmaceuticals (NASDAQ:ACUR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Acura Pharmaceuticals (NASDAQ:ACUR)
Insider Ownership Percentage: 7.40%
Institutional Ownership Percentage: 31.23%
Insider Trades by Quarter for Acura Pharmaceuticals (NASDAQ:ACUR)
Institutional Ownership by Quarter for Acura Pharmaceuticals (NASDAQ:ACUR)
Insider Trades by Quarter for Acura Pharmaceuticals (NASDAQ:ACUR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/29/2017Albert W BrzeczkoVPBuy10,800$0.47$5,076.00View SEC Filing  
6/17/2015Claudius LlcMajor ShareholderSell104,823$1.08$113,208.84View SEC Filing  
1/12/2015Claudius LlcMajor ShareholderSell171,000$0.62$106,020.00View SEC Filing  
5/22/2014William G SkellyDirectorSell4,600$1.23$5,658.00View SEC Filing  
5/20/2014William G SkellyDirectorSell5,000$1.21$6,050.00View SEC Filing  
5/19/2014Albert W BrzeczkoVPBuy2,000$1.20$2,400.00View SEC Filing  
5/16/2014Bruce F WessonDirectorBuy80,000$1.13$90,400.00View SEC Filing  
5/16/2014James F EmighVPBuy15,000$1.21$18,150.00View SEC Filing  
5/16/2014Peter A ClemensCFOBuy3,000$1.21$3,630.00View SEC Filing  
5/14/2014William G SkellyDirectorSell2,900$1.21$3,509.00View SEC Filing  
5/12/2014William G SkellyDirectorSell5,000$1.25$6,250.00View SEC Filing  
5/8/2014William G SkellyDirectorSell2,500$1.30$3,250.00View SEC Filing  
3/3/2014Claudius LlcMajor ShareholderSell2,500$2.00$5,000.00View SEC Filing  
2/28/2014Claudius LlcMajor ShareholderSell351,260$2.02$709,545.20View SEC Filing  
2/24/2014Claudius LlcMajor ShareholderSell44,019$1.97$86,717.43View SEC Filing  
11/25/2013Albert W BrzeczkoVPBuy1,215$1.70$2,065.50View SEC Filing  
10/10/2013Claudius LlcMajor ShareholderSell4,200$2.05$8,610.00View SEC Filing  
8/27/2013William G SkellyDirectorSell2,000$1.55$3,100.00View SEC Filing  
7/15/2013Care Capital Ii LlcMajor ShareholderSell31,610$2.04$64,484.40View SEC Filing  
7/3/2013Care Capital Ii LlcMajor ShareholderSell14,200$2.00$28,400.00View SEC Filing  
7/2/2013Claudius LlcMajor ShareholderSell200,000$2.15$430,000.00View SEC Filing  
6/27/2013Care Capital Ii LlcMajor ShareholderSell76,281$2.01$153,324.81View SEC Filing  
6/24/2013Care Capital Ii LlcMajor ShareholderSell83,000$2.03$168,490.00View SEC Filing  
6/19/2013Care Capital Ii LlcMajor ShareholderSell114,000$2.12$241,680.00View SEC Filing  
6/17/2013Claudius LlcMajor ShareholderSell20,446$2.15$43,958.90View SEC Filing  
6/14/2013Care Capital Ii LlcMajor ShareholderSell90,000$2.16$194,400.00View SEC Filing  
6/11/2013Care Capital Ii LlcMajor ShareholderSell102,000$2.19$223,380.00View SEC Filing  
6/10/2013Claudius LlcMajor ShareholderSell21,496$2.20$47,291.20View SEC Filing  
6/6/2013Claudius LlcMajor ShareholderSell39,453$2.19$86,402.07View SEC Filing  
6/3/2013Care Capital Ii LlcMajor ShareholderSell148,000$2.24$331,520.00View SEC Filing  
5/31/2013Claudius LlcMajor ShareholderSell31,559$2.25$71,007.75View SEC Filing  
5/29/2013Care Capital Ii LlcMajor ShareholderSell108,701$2.33$253,273.33View SEC Filing  
5/28/2013William G SkellyDirectorSell2,000$2.40$4,800.00View SEC Filing  
5/23/2013Care Capital Ii LlcMajor ShareholderSell252,000$2.31$582,120.00View SEC Filing  
5/22/2013William G SkellyDirectorSell4,000$2.33$9,320.00View SEC Filing  
5/21/2013Claudius LlcMajor ShareholderSell47,410$2.30$109,043.00View SEC Filing  
5/20/2013Care Capital Ii LlcMajor ShareholderSell510,000$2.36$1,203,600.00View SEC Filing  
5/16/2013Care Capital Ii LlcMajor ShareholderSell662,000$2.38$1,575,560.00View SEC Filing  
5/16/2013William G SkellyDirectorSell3,000$2.25$6,750.00View SEC Filing  
5/15/2013Claudius LlcMajor ShareholderSell183,434$2.33$427,401.22View SEC Filing  
5/13/2013Care Capital Ii LlcMajor ShareholderSell259,000$2.19$567,210.00View SEC Filing  
5/9/2013William G SkellyDirectorSell3,000$2.20$6,600.00View SEC Filing  
4/11/2013Claudius LlcMajor ShareholderSell121,454$2.23$270,842.42View SEC Filing  
3/26/2013Care Capital Ii LlcMajor ShareholderSell39,554$2.17$85,832.18View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Acura Pharmaceuticals (NASDAQ:ACUR)
Latest Headlines for Acura Pharmaceuticals (NASDAQ:ACUR)
Source:
DateHeadline
globenewswire.com logoAcura Pharmaceuticals Presenting New LIMITx™ Clinical Data at the 19th Annual Rodman & Renshaw Conference - GlobeNewswire (press release)
globenewswire.com - September 13 at 3:43 PM
nasdaq.com logoAcura Pharmaceuticals Presenting New LIMITx™ Clinical Data at the 19th Annual Rodman & Renshaw Conference - Nasdaq
www.nasdaq.com - September 11 at 4:02 PM
finance.yahoo.com logoAcura Pharmaceuticals Presenting New LIMITx™ Clinical Data at the 19th Annual Rodman & Renshaw Conference
finance.yahoo.com - September 11 at 4:02 PM
americanbankingnews.com logo Analysts Anticipate Acura Pharmaceuticals, Inc. (ACUR) Will Announce Earnings of -$0.12 Per Share
www.americanbankingnews.com - September 9 at 6:20 PM
finance.yahoo.com logoETFs with exposure to Acura Pharmaceuticals, Inc. : September 7, 2017
finance.yahoo.com - September 7 at 3:26 PM
finance.yahoo.com logoETFs with exposure to Acura Pharmaceuticals, Inc. : September 7, 2017
finance.yahoo.com - September 7 at 3:26 PM
finance.yahoo.com logoAcura Pharmaceuticals, Inc. :ACUR-US: Earnings Analysis: Q2, 2017 By the Numbers : September 5, 2017
finance.yahoo.com - September 5 at 3:43 PM
nasdaq.com logoAcura Pharmaceuticals to Present at the 19th Annual RODMAN & RENSHAW Conference - Nasdaq
www.nasdaq.com - August 31 at 3:24 PM
nasdaq.com logoAcura Pharmaceuticals to Present at the 19th Annual RODMAN & RENSHAW Conference - Nasdaq
www.nasdaq.com - August 31 at 3:23 PM
finance.yahoo.com logoAcura Pharmaceuticals to Present at the 19th Annual RODMAN & RENSHAW Conference
finance.yahoo.com - August 31 at 3:23 PM
finance.yahoo.com logoAcura Pharmaceuticals to Present at the 19th Annual RODMAN & RENSHAW Conference
finance.yahoo.com - August 31 at 3:23 PM
finance.yahoo.com logoEdited Transcript of ACUR earnings conference call or presentation 15-Aug-17 12:30pm GMT
finance.yahoo.com - August 15 at 8:49 PM
seekingalpha.com logoAcura Pharmaceuticals' (ACUR) CEO Bob Jones on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 15 at 3:47 PM
finance.yahoo.com logoInvestor Network: Acura Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - August 15 at 3:47 PM
americanbankingnews.com logoAcura Pharmaceuticals, Inc. (ACUR) Issues Quarterly Earnings Results
www.americanbankingnews.com - August 15 at 9:41 AM
globenewswire.com logoAcura Pharmaceuticals Announces Second Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - August 14 at 8:44 PM
finance.yahoo.com logoAcura Pharmaceuticals Announces Second Quarter 2017 Financial Results
finance.yahoo.com - August 14 at 8:44 PM
americanbankingnews.com logoZacks: Analysts Anticipate Acura Pharmaceuticals, Inc. (ACUR) to Announce -$0.11 Earnings Per Share
www.americanbankingnews.com - August 4 at 7:44 AM
streetinsider.com logoForm 8-K ACURA PHARMACEUTICALS, For: Jul 28 - StreetInsider.com
www.streetinsider.com - August 3 at 3:57 PM
nasdaq.com logoAcura Pharmaceuticals to Host Second Quarter 2017 Financial Results Conference Call on August 15, 2017 - Nasdaq
www.nasdaq.com - August 3 at 3:57 PM
americanbankingnews.com logoAcura Pharmaceuticals (NASDAQ:ACUR) vs. Flamel Technologies (AVDL) Financial Comparison
www.americanbankingnews.com - August 3 at 10:16 AM
feeds.benzinga.com logoAcura Pharmaceuticals to Host Second Quarter 2017 Financial Results Conference Call on August 15, 2017
feeds.benzinga.com - August 3 at 6:13 AM
americanbankingnews.com logoHead to Head Analysis: Flamel Technologies (AVDL) vs. Acura Pharmaceuticals (NASDAQ:ACUR)
www.americanbankingnews.com - August 2 at 4:34 PM
americanbankingnews.com logoReviewing Acura Pharmaceuticals (ACUR) and Flamel Technologies (AVDL)
www.americanbankingnews.com - August 2 at 12:16 AM
americanbankingnews.com logoHead to Head Contrast: Flamel Technologies (AVDL) & Acura Pharmaceuticals (NASDAQ:ACUR)
www.americanbankingnews.com - August 2 at 12:16 AM
americanbankingnews.com logoFlamel Technologies (AVDL) & Acura Pharmaceuticals (NASDAQ:ACUR) Critical Comparison
www.americanbankingnews.com - July 31 at 9:07 AM
americanbankingnews.com logoComparing Acura Pharmaceuticals (ACUR) & Flamel Technologies (AVDL)
www.americanbankingnews.com - July 30 at 12:20 PM
americanbankingnews.com logoFlamel Technologies (AVDL) and Acura Pharmaceuticals (ACUR) Head to Head Survey
www.americanbankingnews.com - July 28 at 8:25 PM
americanbankingnews.com logoReviewing Flamel Technologies (AVDL) & Acura Pharmaceuticals (NASDAQ:ACUR)
www.americanbankingnews.com - July 26 at 8:34 AM
finance.yahoo.com logoAcura Pharmaceuticals Raises $4.0 Million in a Private Placement
finance.yahoo.com - July 24 at 6:54 PM
americanbankingnews.com logoComparing Flamel Technologies (AVDL) & Acura Pharmaceuticals (NASDAQ:ACUR)
www.americanbankingnews.com - July 24 at 6:04 PM
americanbankingnews.com logoFlamel Technologies (AVDL) vs. Acura Pharmaceuticals (NASDAQ:ACUR) Head to Head Analysis
www.americanbankingnews.com - July 23 at 6:20 PM
americanbankingnews.com logoAnalyzing Flamel Technologies (AVDL) & Acura Pharmaceuticals (NASDAQ:ACUR)
www.americanbankingnews.com - July 22 at 7:38 AM
americanbankingnews.com logoFinancial Analysis: Acura Pharmaceuticals (NASDAQ:ACUR) vs. Flamel Technologies (AVDL)
www.americanbankingnews.com - July 21 at 8:32 AM
americanbankingnews.com logoContrasting Flamel Technologies (AVDL) & Acura Pharmaceuticals (ACUR)
www.americanbankingnews.com - July 19 at 8:40 PM
americanbankingnews.com logoZacks: Analysts Expect Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) Will Announce Earnings of -$0.11 Per Share
www.americanbankingnews.com - July 12 at 8:45 PM
americanbankingnews.com logoCritical Review: Flamel Technologies (AVDL) & Acura Pharmaceuticals (ACUR)
www.americanbankingnews.com - July 11 at 12:20 AM
americanbankingnews.com logoCritical Contrast: Flamel Technologies (AVDL) & Acura Pharmaceuticals (NASDAQ:ACUR)
www.americanbankingnews.com - July 8 at 7:51 AM
reuters.com logoBRIEF-Bayer Healthcare terminates Acura's license, development agreement
www.reuters.com - July 5 at 8:43 PM
finance.yahoo.com logoAcura Pharmaceuticals Advances LTX-04 and its LIMITx™ Technology
finance.yahoo.com - June 28 at 8:43 PM
americanbankingnews.com logo-$0.11 Earnings Per Share Expected for Acura Pharmaceuticals, Inc. (ACUR) This Quarter
www.americanbankingnews.com - June 16 at 8:46 PM
seekingalpha.com logoEgalet: A High Risk/High Reward ~$2.50 Biopharma Stock
seekingalpha.com - June 16 at 2:54 AM
americanbankingnews.com logoAnalyzing Aradigm (ARDM) & Acura Pharmaceuticals (ACUR)
www.americanbankingnews.com - June 10 at 12:30 AM
americanbankingnews.com logoZacks: Acura Pharmaceuticals, Inc. (ACUR) Given Consensus Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - June 8 at 8:50 AM
americanbankingnews.com logoHead-To-Head Comparison: Aradigm (ARDM) versus Acura Pharmaceuticals (ACUR)
www.americanbankingnews.com - June 7 at 2:20 PM
finance.yahoo.com logoAcura Pharmaceuticals, Inc. :ACUR-US: Earnings Analysis: Q1, 2017 By the Numbers : May 24, 2017
finance.yahoo.com - May 24 at 3:18 PM
streetinsider.com logoAcura Pharma (ACUR) Reports Initiation of Second Clinical Study on LTX-04
www.streetinsider.com - May 19 at 3:20 PM
finance.yahoo.com logoAcura Pharmaceutical Initiates Second Clinical Study on LTX-04
finance.yahoo.com - May 19 at 9:48 AM
americanbankingnews.com logoAcura Pharmaceuticals, Inc. (ACUR) Releases Quarterly Earnings Results, Beats Estimates By $0.14 EPS
www.americanbankingnews.com - May 15 at 11:30 AM
americanbankingnews.com logoAcura Pharmaceuticals (ACUR) Given Coverage Optimism Score of 0.07
www.americanbankingnews.com - May 2 at 9:25 AM

Social

Chart

Acura Pharmaceuticals (ACUR) Chart for Wednesday, September, 20, 2017

This page was last updated on 9/20/2017 by MarketBeat.com Staff